CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

A reporter uncovers evidence that research fraud on a massive scale has hyped the potential benefit of expensive drugs aimed ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Citi analysts adjusted their outlook on Eisai Co Ltd (OTC:ESAIY). (4523:JP) (OTC: ESALY), reducing the price target from JPY6,000 to JPY5,000, while continuing to endorse the stock with a Buy rating.

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates. The ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...

The first drug proven to slow down Alzheimer's won't be available to dementia patients in Scotland - unless they pay £60,000 ...

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates.

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...